




PHARMACEUTICAL 2019

MANNKIND CORP
Rank 322 of 363

mannkind





PHARMACEUTICAL 2019

MANNKIND CORP
Rank 322 of 363

mannkind

The relative strengths and weaknesses of MANNKIND CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MANNKIND CORP compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 31% points. The greatest weakness of MANNKIND CORP is the variable Other Liabilities, reducing the Economic Capital Ratio by 119% points.

The company's Economic Capital Ratio, given in the ranking table, is -199%, being 236% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	81,854
Cost of Goods Sold	19,402
Intangible Assets	0
Liabilities, Current	75,241
Liabilities, Non-Current	10,680
Other Assets	249
Other Compr. Net Income	-1.0
Other Expenses	-3,161
Other Liabilities	196,866
Other Net Income	-10,140
Other Revenues	27,859
Property and Equipment	25,602
Research and Development	8,737
Selling, General and Administrative Expense	79,716

Output Variable	Value in 1000 USD
Assets	107,705
Liabilities	282,787
Expenses	104,694
Revenues	27,859
Stockholders Equity	-175,082
Net Income	-86,975
Comprehensive Net Income	-86,976
Economic Capital Ratio	-199%